![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Two applications from Millennium Pharm. and Kyowa Hakko describe CCR1 antagonists incorporating a 4-(4-chlorophenyl)-1-[4-phenyl-4-(pyrid-3-yl)but-3-enyl]piperidin-4-ol motif. These applications disclose additional compounds over earlier applications in this series (from Leukosite) and may well describe the candidate that is now in preclinical development as a candidate for the treatment of rheumatoid arthritis.